Form 4: Ionis Pharma EVP Reports RSU Vesting and Tax Sale

Ionis Pharmaceuticals' EVP, Chief Development Officer, Holly Kordasiewicz, reported the vesting of restricted stock units, a subsequent sale to cover tax obligations, and new RSU grants.

Summary

• Holly B. Kordasiewicz, EVP, Chief Development Officer of Ionis Pharmaceuticals, Inc. (IONS), reported transactions involving the company's common stock and restricted stock units (RSUs).
• On January 15, 2026, 11,119 shares of common stock were acquired due to the vesting and release of Restricted Stock Unit awards.
• Following this acquisition, Kordasiewicz's direct beneficial ownership of common stock was 18,859 shares.
• On January 16, 2026, 4,141 shares of common stock were disposed of at a weighted average price of $75.66 per share, ranging from $75.63 to $75.72.
• This sale was an automatic transaction to cover required tax withholding obligations related to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
• After the tax-related sale, Kordasiewicz's direct beneficial ownership of common stock was 14,718 shares.
• On January 15, 2026, 11,119 Restricted Stock Units (RSUs) were exercised/vested, representing a contingent right to receive one share of Ionis common stock.
• Additionally, on January 15, 2026, Kordasiewicz was granted two new Restricted Stock Unit awards: one for 13,650 units and another for 11,250 units.
• These new RSU grants vest in four equal annual installments, with the first vesting date for these specific grants being January 15, 2027.
• Following all reported transactions, Kordasiewicz beneficially owns 45,730 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation, including RSU vesting, a tax-related sale, and new RSU grants, which are standard and do not indicate significant positive or negative operational news.

Positives

• The grant of new Restricted Stock Units (13,650 and 11,250 units) indicates continued executive compensation and retention of a key management member.
• The vesting of RSUs represents a successful milestone for previously granted compensation.

Negatives

• A sale of 4,141 shares of common stock, even for tax purposes, reduces the direct beneficial ownership of the EVP, Chief Development Officer.

Industry Context

This announcement reflects standard executive compensation practices within the biotechnology and pharmaceutical industries, where Restricted Stock Units are a common form of equity-based incentive. The automatic sale of shares to cover tax obligations upon RSU vesting is also a routine and expected event for executives in publicly traded companies.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a widespread practice across publicly traded companies, including those in the biotechnology sector, aligning executive incentives with shareholder value.
• The automatic sale of shares to cover tax withholding obligations upon RSU vesting is a standard and common procedure, often pre-arranged under Rule 10b5-1 plans, to manage the tax liabilities associated with equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, pre-scheduled compensation-related transactions that do not reflect new operational or strategic developments.
• Employees: Reflects standard executive compensation practices, which may be viewed as consistent with company policy.

Next Steps

• Future vesting of the newly granted Restricted Stock Units will occur in four equal annual installments, with the first installment on January 15, 2027.

Key Dates

Recommendation

This Form 4 details routine executive compensation activities, including RSU vesting and a tax-related share sale, which are standard and do not provide new information to alter the investment outlook for Ionis Pharmaceuticals. The transactions are expected and do not reflect operational performance or strategic shifts, thus a 'hold' recommendation is appropriate as there's no new fundamental catalyst.

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Vesting, Executive Compensation, Tax Withholding, Holly Kordasiewicz